Quarterly Result26 May 2026, 01:15 pm
Marksans Pharma: Final Dividend of ₹0.90 Recommended
AI Summary
Marksans Pharma Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board of Directors recommended a final dividend of ₹0.90 per equity share of face value ₹1. The dividend, if approved at the AGM, will be credited/dispatched within 30 days. The Statutory Auditors, MSKA & Associates LLP, issued an unmodified opinion on the financial results.
Key Highlights
- Audited financial results approved for quarter and year ended March 31, 2026.
- Final dividend of ₹0.90 per share recommended for FY 2025-26.
- Auditors, MSKA & Associates LLP, issued an unmodified opinion.
- Meeting commenced at 11:55 AM and concluded at 12:45 PM on May 26, 2026.
Price Impact
More from MARKSANS